drugset / Trial / NCT06417853
Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)
Phase 1
Completed
267 enrolled
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy adults aged 18 to 50 years.
Timeline
- Start
- 2024-07-31
- Primary completion
- 2026-01-30
- Completion
- 2026-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MF59 | Other / unclassified | — | Intramuscular |
| Subject | QS-21 | Other / unclassified | 3.3 ug | — |
| Subject | QS-21 | Other / unclassified | 4 ug | — |
| Subject | QS-21 | Other / unclassified | 6.7 ug | — |
| Subject | QS-21 | Other / unclassified | 8 ug | — |
| Comparator | VXS-1219 | Unknown | 7.5 ug | Intramuscular |
| Comparator | VXS-1219 | Unknown | 12 ug | Intramuscular |
| Comparator | VXS-1219 | Unknown | 20 ug | Intramuscular |
| Comparator | VXS-1219 | Unknown | 25 ug | Intramuscular |